



HU000026271T2

(19) **HU**(11) Lajstromszám: **E 026 271**(13) **T2****MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**  
**SZÖVEGÉNEK FORDÍTÁSA**

(21) Magyar ügyszám: **E 11 736202**  
(22) A bejelentés napja: **2011. 06. 20.**  
(96) Az európai bejelentés bejelentési száma:  
**EP 20110736202**  
(97) Az európai bejelentés közzétételi adatai:  
**EP 2616444 A2** **2012. 03. 22.**  
(97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2616444 B1** **2015. 08. 26.**

(51) Int. Cl.: **C07D 219/10** (2006.01)  
**A61K 314/35** (2006.01)  
**A61K 316/63** (2006.01)  
**C07D 401/12** (2006.01)  
**C07D 473/30** (2006.01)  
**C07F 9/30** (2006.01)  
**C07D 473/22** (2006.01)  
**C07C 233/65** (2006.01)  
**C07C 235/84** (2006.01)

(86) A nemzetközi (PCT) bejelentési szám:  
**PCT/PL 11/000060**

(87) A nemzetközi közzétételi szám:  
**WO 12036573**

(30) Elsőbbségi adatok: <b>39239610 P</b> <b>2010. 09. 14.</b> <b>PL</b> <b>39239710 P</b> <b>2010. 09. 14.</b> <b>PL</b>	(73) Jogosult(ak): <b>Instytut Biochemii i Biofizyki PAN, 02-106</b> <b>Warszawa (PL)</b>
(72) Feltaláló(k): <b>ODOLCZYK, Norbert, 02-595 Warszawa (PL)</b> <b>ZIELENKIEWICZ, Piotr, 00-248 Warszawa (PL)</b> <b>WIECZOREK, Grzegorz, 01-493 Warszawa (PL)</b> <b>EDELMAN, Aleksander, 92290 Chatenay-Malabry (FR)</b> <b>TONDELIER, Danielle, 78600 Le Mesnil-le-Roi (FR)</b> <b>FRITSCH, Janine, 91240 Saint Michel sur Orge (FR)</b>	(74) Képvisező: <b>Szentpéteri Zsolt, SBGK Szabadalmi Ügyvivői</b> <b>Iroda, Budapest</b>

(54) **Mutáns CFTR protein modulátor vegyületek és azok alkalmazása CFTR protein működési rendellenességgel összefüggő betegségek kezelésére**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 616 444 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:  
**26.08.2015 Bulletin 2015/35**

(21) Application number: **11736202.0**

(22) Date of filing: **20.06.2011**

(51) Int Cl.:  
**C07D 219/10** (2006.01) **C07D 473/30** (2006.01)  
**C07F 9/30** (2006.01) **C07C 233/65** (2006.01)  
**A61K 31/663** (2006.01) **A61K 31/435** (2006.01)  
**C07D 401/12** (2006.01) **C07D 473/22** (2006.01)  
**C07C 235/84** (2006.01)

(86) International application number:  
**PCT/PL2011/000060**

(87) International publication number:  
**WO 2012/036573 (22.03.2012 Gazette 2012/12)**

(54) **COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION**

VERBINDUNGEN ALS MODULATOREN EINES MUTANTEN CFTR-PROTEINS UND IHRE VERWENDUNG ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT EINER CFTR-PROTEINFEHLFUNKTION

COMPOSÉS MODULATEURS D'UNE PROTÉINE CFTR MUTANTE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES ASSOCIÉES À UN DYSFONCTIONNEMENT DE LA PROTÉINE CFTR

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(30) Priority: **14.09.2010 PL 39239610 P**  
**14.09.2010 PL 39239710 P**

(43) Date of publication of application:  
**24.07.2013 Bulletin 2013/30**

(60) Divisional application:  
**14185330.9 / 2 826 771**  
**14185332.5 / 2 816 034**  
**14185333.3 / 2 816 035**

(73) Proprietor: **Instytut Biochemii i Biofizyki PAN**  
**02-106 Warszawa (PL)**

(72) Inventors:  
• **ODOLCZYK, Norbert**  
**02-595 Warszawa (PL)**  
• **ZIELENKIEWICZ, Piotr**  
**00-248 Warszawa (PL)**  
• **WIECZOREK, Grzegorz**  
**01-493 Warszawa (PL)**

• **EDELMAN, Aleksander**  
**92290 Chatenay-Malabry (FR)**  
• **TONDELIER, Danielle**  
**78600 Le Mesnil-le-Roi (FR)**  
• **FRITSCH, Janine**  
**91240 Saint Michel sur Orge (FR)**

(74) Representative: **Twardowska, Aleksandra**  
**Kulikowska & Kulikowski**  
**Roma Office Center**  
**ul.Nowogrodzka 47A**  
**00-695 Warszawa (PL)**

(56) References cited:  
**WO-A1-2008/122038 WO-A1-2010/059215**  
**WO-A2-2006/002421 WO-A2-2007/075901**

• **DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WYSTRACH, VERNON P.: "Chemical treatment of metal", XP002668823, retrieved from STN Database accession no. 1974:84838 & US 3 770 514 A (WYSTRACH, VERNON P.) 6 November 1973 (1973-11-06)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 616 444 B1**

- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SINGH, GURDIAL ET AL: "A thermolysis study of poly(trimethylene phenylphosphinate) and poly(2,2-dimethyltrimethylene phenylphosphinate). NMR and x-ray structure of 2-oxo-2-phenyl-4,4-dimethyl-1,2-oxaphospho lane", XP002668824, retrieved from STN Database accession no. 1985: 24736 & SINGH, GURDIAL ET AL: "A thermolysis study of poly(trimethylene phenylphosphinate) and poly(2,2-dimethyltrimethylene phenylphosphinate). NMR and x-ray structure of 2-oxo-2-phenyl-4,4-dimethyl-1,2-oxaphospho lane", JOURNAL OF ORGANIC CHEMISTRY, 49 (26), 5132-6 CODEN: JOCEAH; ISSN: 0022-3263, 1984,
- DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CAMPBELL, ISHBEL G. M. ET AL: "Reaction of phenylphosphonous acid with carbonyl compounds", XP002668825, retrieved from STN Database accession no. 1971:436257 & CAMPBELL, ISHBEL G. M. ET AL: "Reaction of phenylphosphonous acid with carbonyl compounds", JOURNAL OF THE CHEMICAL SOCIETY [SECTION] C: ORGANIC, (10), 1836-40 CODEN: JSOAX; ISSN: 0022-4952, 1971,
- DATABASE REAXYS [Online] Elsevier; 1965, Mastalerz: XP002668819, & MASTALERZ: ROCZNIKI CHEMII, vol. 39, 1965, pages 1129-1130,
- SOMMER K: "ZUR SPALTUNG TERTIAERER PHOSPHINE", ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, vol. 376, no. 37, 1 January 1970 (1970-01-01), pages 37-43, XP001021410, ISSN: 0044-2313, DOI: 10.1002/ZAAC.19703760106
- KYBA ET AL: "A novel synthesis of 1,2-diphosphorylbenzenes", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 20, 1 January 1981 (1981-01-01), pages 1875-1878, XP002192247, ISSN: 0040-4039, DOI: 10.1016/S0040-4039(01)90465-4
- ABRAMOV V S ET AL: "Reactions of Sodium Alkyl Phenylphosphonites with some Dihalogen Compounds", JOURNAL OF GENERAL CHEMISTRY USSR, CONSULTANTS BUREAU, NEW YORK, NY, US, vol. 38, no. 7, 1 July 1968 (1968-07-01), pages 1748-1751, XP008148333, ISSN: 0022-1279
- YU Y ET AL: "Stereochemistry of Organophosphorus Compounds VII. Configurations and Features of PMR Spectra of Some Unsaturated Compounds Containing Two Phosphorus Atoms", JOURNAL OF GENERAL CHEMISTRY USSR, CONSULTANTS BUREAU, NEW YORK, NY, US, vol. 45, 1 January 1975 (1975-01-01), pages 2097-2101, XP008148380, ISSN: 0022-1279
- BAKER B R ET AL: "Irreversible enzyme inhibitors. XCV. 8-(m-Bromoacetamidobenzylthio)hypoxanthine, an active-site-directed irreversible inhibitor of xanthine oxidase", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 10, no. 4, 1 July 1967 (1967-07-01), pages 682-685, XP002972010, ISSN: 0022-2623, DOI: 10.1021/JM00316A035
- JIANG H ET AL: "Stabilizers of the max homodimer identified in virtual ligand screening inhibit Myc function", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 76, no. 3, 1 January 2009 (2009-01-01), pages 491-502, XP008132859, ISSN: 0026-895X
- ZHAOHUI YAN ET AL: "Identification of an Aminoacridine Derivative That Binds to RNA Tetraloops", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 17, 1 August 2007 (2007-08-01), pages 4096-4104, XP55028583, ISSN: 0022-2623, DOI: 10.1021/jm070305p
- Norbert Odolczyk ET AL: "Discovery of novel potent [Delta]F508-CFTR correctors that target the nucleotide binding domain", EMBO Molecular Medicine, vol. 5, no. 10, 27 October 2013 (2013-10-27), pages 1484-1501, XP055126570, ISSN: 1757-4676, DOI: 10.1002/emmm.201302699

## Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

## Description

**[0001]** The present invention relates to novel protein modulators capable of altering function of the mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction. The invention provides compositions, pharmaceutical preparations and methods of correcting the cellular alteration of a mutant CFTR protein wherein the CFTR mutation is a mutation  $\Delta F508$ -CFTR, or another mutation of class II.

**[0002]** Cystic fibrosis (also known as CF or mucoviscidosis) is one of the most common, fatal genetic diseases in humans. CF is an inherited autosomal recessive genetic disease that affects around 1 child in 2,500 live births (1). CF is caused by mutations in the *cftr* gene that encodes the cystic fibrosis transmembrane conductance regulator (CFTR protein) with activity as an epithelial chloride ion channel (2, 3). As a result of impaired function of this protein appear severe symptoms associated with respiratory and digestive systems and male reproductive system (4). Hitherto, more than 1600 mutations in CFTR gene have been identified and described (5).

**[0003]** The *CFTR* gene mutations were classified into five classes based on the molecular mechanisms leading to the CFTR protein malfunction (6,7). The class I mutations contribute to the formation of proteins with incomplete length and usually involve the complete loss of its activity (e.g. G542X). Mutation in the class II leading to abnormal maturation of proteins in the endoplasmic reticulum and Golgi apparatus. The effect of these mutations is premature degradation of the protein. Hence, CFTR does not reach the cell membrane where it should perform its function (eg,  $\Delta F508$ ,  $\Delta I507$ , S549R) (8). The gene product having mutations of class III is properly synthesized, transported and incorporated into the cell membrane, but has decreased activity caused by abnormal regulation of the protein.

**[0004]** These mutations are frequently situated within one of the nucleotide binding domain. (eg. G551D/S). Mutations of class IV cause anomalies in the structure of the transmembrane protein and thereby reduce the conduction of chloride channel (e.g. R117H, R334W). Mutations altering the stability of mRNA represent a class V of the mutations of the *CFTR* gene (3849+10kbC->T,5T).

**[0005]** The most prevalent mutation present in at least one allele in approximately 90% of patients (9) is a deletion of phenylalanine at position 508 of the CFTR amino acid sequence ( $\Delta F508$  CFTR). This is a classic example of class II mutation that causes premature degradation of the protein (8, 10). This mutation is associated with water-electrolyte disturbances (among others with chloride anion flux out of a cell across the plasma membrane (11) and the movement of sodium ions into the cell (12)) and results in the appearance of pathological symptoms. Some of the most severe symptoms include congestion and increased mucus viscosity in the upper and lower airways leading to lung damage. These conditions create a favorable environment for development of bacterial infections caused by e.g. *Pseudomonas aeruginosa*. Moreover, malfunction of CFTR protein leads to obstruction of exocrine pancreatic ducts and related digestive disorders (13).

**[0006]** CFTR is a glycoprotein with 1480 amino acids and classified as an ABC (ATP-binding cassette) transporter. The protein consists of five domains. There are two nucleotide binding domains (NBD1 and NBD2), regulatory domain (RD) and two transmembrane domains (TMD1 and TMD2). The protein activity is regulated by cAMP-dependent Protein Kinase (PKA) which catalyze phosphorylation of regulatory domain (RD) and also by binding of two ATP molecules to NBD1 and NBD2 domains (14).

**[0007]** The invention described in the patent application WO2007075901 (publ. 2007-07-05) relates to prodrugs of modulators of ABC transporters, particularly, CFTR modulators, compositions thereof, and methods therewith. The invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

**[0008]** In a publication WO2005120497 (US20080319008), compounds that increase activity (ion transport) of a mutant CFTR protein, and uses thereof are described. The invention also provides compositions, pharmaceutical preparations and methods increasing ion transport activity of a mutant CFTR protein, i.e.  $\Delta F508$  CFTR, G551D-CFTR, G1349D-CFTR or D1152H-CFTR, that are useful in treating cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds or an analog or derivatives thereof.

**[0009]** In a publication WO2009051910, compounds that increase ion transport activity of a mutant CFTR protein, and uses thereof are described. The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant-CFTR. The compositions pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds, or an analog or derivative thereof.

**[0010]** The patent application US5948814 describe use of genistein compound for treatment of CF. A method of treating cystic fibrosis by generating CFTR function in cells containing mutant CFTR and the therapeutic composition for treatment are described. The method of treatment comprising administering an effective amount of genistein, or genistein analogues and derivatives, to a patient afflicted with cystic fibrosis.

**[0011]** In patent application US20040006127, method for activation of the chloride is described. Fluorescein and derivatives have use in the treatment of a disease of condition of a living animal body, including human, which disease

is responsive to the activation of the CFTR chloride channels, for instance cystic fibrosis, disseminated bronchiectasis, pulmonary infections, chronic pancreatitis, male infertility and long QT syndrome.

**[0012]** In a publication WO2006101740 (US20080318984) compounds for correction of the cellular alteration of a mutant CFTR protein and uses thereof are described. The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing of a mutant-CFTR protein (e.g.,  $\Delta$ F508 CFTR) that are useful for the treatment of cystic fibrosis. The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinyaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquinoline-containing compounds, or an analog or derivative thereof.

**[0013]** In a publication WO2009051909, compounds that improve the cellular alteration of a mutant CFTR protein and uses thereof are described. The invention provides compositions, pharmaceutical preparations and methods for increasing activity of a mutant-CFTR. The compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The compositions of the invention may comprise one or more bithiazole-containing compounds of the invention, or an analog or derivative thereof.

**[0014]** Phenylalanine 508 in CFTR protein occurs on the surface of NBD1 domain of CFTR.


**[0015]** Current structural and biophysical studies reveal no significant differences between wild-domain protein, and  $\Delta$ F508 mutant domain that may affect the folding kinetics and thermodynamic stability of CFTR protein. Solved crystal structures of both domains show only slight differences in the reorganization of the amino acids located near the site, which should be occupied by F508 (10).

**[0016]** The purpose of this invention is to provide compositions, pharmaceutical preparations and methods of correcting the cellular processing of mutant CFTR protein. F508 deletion has minimal effect on the structure of NBD1 domain as have been observed in the results of X-ray and cannot explain the dramatic difference in the behavior of mutant and native forms of CFTR protein in the cell. For the purposes of the present invention, the structural data of both forms of protein were subjected to computer simulation designed to determine the dynamic properties of NBD1. In the present invention the molecular dynamics methods, have been used. This method is based on an iterative calculation of the interactions between the atoms forming the simulated system and solving equations of motion (15). These simulations (for both studied forms of NBD1) results in sets of structures that can be adopted by the target protein according to the initial physical assumptions - the so-called trajectories.

**[0017]** Based on the analysis of molecular dynamics trajectories of the two domains it was possible to isolate a mutant protein conformation, which differs significantly from the conformational states adopted by the wild protein. The conformation possesses the two major pockets on the surface of the protein located on both sides of the ATP binding site. The structure of protein in this conformation was used to develop compounds for the correction of  $\Delta$ F508-CFTR activity.

**[0018]** Realization of purpose of the invention, and the solution of problems associated with the compounds actually used for the treatment of cystic fibrosis, as have been described in the prior art, have been achieved in the present invention with the highest efficiency of the process.

**[0019]** The subject matter of invention is a compound of general formula (I):



its tautomers, E and Z geometrical isomers, optically active forms such as enantiomers, diastereomers and their racemate forms or a mixture of stereoisomeric forms or its pharmaceutically acceptable salts thereof or complexes thereof; wherein  $Z^1$  is independently selected from the group consisting of:

$-\text{C}_n\text{H}_{(2n)-}$ , which is branched or unbranched wherein n is an integer from 1 to 5;  $-\text{C}_n\text{H}_{(2n-2)-}$  in E or Z geometrical conformation which is branched or unbranched wherein n is an integer from 2 to 5;  $-\text{C}_n\text{H}_{(2n-4)-}$  which is branched or unbranched wherein n is an integer from 2 to 5;  $-\text{CR}'\text{H}-$ ,  $-\text{C}_2\text{H}_3\text{R}'-$ , E or Z- $\text{C}_2\text{HR}'-$ ,  $-\text{C}_3\text{H}_5\text{R}'-$ , E or Z- $\text{C}_3\text{H}_3\text{R}'-$ ,  $-\text{OCH}_2-$ ,  $-\text{CH}_2\text{O}-$ ,  $\text{NR}''\text{CH}_2-$ ,  $-\text{CH}_2\text{NR}''-$ ; wherein R' is independently selected from the group consisting of: -H, halogen,  $-\text{NH}_2$ , -OH, -CN,  $\text{CF}_3$ ,  $-\text{CHF}_2$ ,  $-\text{CH}_2\text{F}$ , -SH, -SCN,  $-\text{CH}_3$ ,  $-\text{C}_2\text{H}_5$ ; wherein R'' is independently selected from the group consisting of: -H,  $-\text{CH}_3$ ,  $-\text{C}_2\text{H}_5$ ; wherein  $\text{R}^1$  and  $\text{R}^2$  are independently selected from the group consisting of aromatic ring or heteroaromatic ring,

as a modulator of a mutant CFTR protein for use in the treatment of cystic fibrosis.

[0020] Preferably,  $R^1$  and  $R^2$  are independently selected from the group of sub-formula (1a):



10 wherein  $A_1, A_2, A_3, A_4, A_5, A_6$  is independently selected N or C atoms wherein ring contain 0-3 nitrogen atoms; wherein  $E^1, E^2, E^3, E^4, E^5$  represents optional substituents, which are selected from:  $-OR_B, -OC(=O)R_C, -OC(=O)OR_B,$   
 $-OC(=O)N(R_A)R_{A'}, -C(=O)R_C, -C(=O)N(R_A)R_{A'}, -C(=O)N(OR_B)R_A, -C(=O)OR_B, -C(=S)R_C, -C(=O)C(=O)R_C, -CH_2OR_B,$   
 $-CH_2CH_2OR_B, -CH_2N(R_A)R_{A'}, -CH_2CH_2N(R_A)R_{A'}, -CH_2OCH_2R_C, -CH_2N(R_A)CH_2R_C, -SR_D, -S(=O)R_D, -SO_2R_D,$   
 $-SO_2N(R_A)R_{A'}, -SO_3R_B, -N(R_A)C(=O)R_C, -N(R_A)C(=O)OR_B, -N(R_A)C(=O)N(R_{A'})R_{A'"}, -N(R_A)SO_2R_D,$   
 $-N(R_A)SO_2N(R_{A'})R_{A'"}, -N(R_A)R_{A'"}, -N(R_A)C(=O)R_C, -N(R_A)C(=O)OR_B, -N(R_A)N(R_{A'})R_{A'"}, -N(R_{A'})N(R_A)C(=O)R_C, -NO_2,$   
 $-CN, -CF_3, -CHF_2, -CH_2F, -NH_2, -SCN, -SO_2CN, -F, Cl, -Br, -I, -PO_3H_2, -OPO_3H_2, -C_nH_{2n}R_C$  which is branched or unbranched wherein  $n$  is an integer from 1 to 5;  $-C_nH_{(2n-2)}R_C$  in E or Z geometrical conformation which branched or unbranched


15 wherein  $n$  is an integer from 2 to 5;  $-C_nH_{(2n-4)}R_C$  which is branched or unbranched wherein  $n$  is an integer from 2 to 5; wherein  $R_A, R_{A'}, R_{A'}$  are each independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3,$   
 $-CHF_2, -CH_2F, -OH;$

20 wherein  $R_B$  is independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3, -CHF_2, -CH_2F,$   
 $-CH_2Cl, -CH_2Br, -CH_2I;$

25 wherein  $R_C$  is independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3, -CHF_2, -CH_2F,$   
 $-CH_2Cl, -CH_2Br, -CH_2I, -F, -Cl, -Br, -I, -NH_2,$

wherein  $R_D$  is independently selected from the group consisting of:  $-H,$  lower alkyl group;

[0021] Preferably, said compound being represented by the following structures:



40 [0022] Preferably, it has effect on mutant CFTR protein, wherein said CFTR mutation is a mutation  $\Delta F508$ -CFTR, or another mutation of class II and where a mutation  $\Delta F508$ -CFTR, or another mutation of class II are involved in CFTR protein malfunction. Preferably, the disease associated with CFTR protein malfunction is cystic fibrosis.

45 [0023] The next subject of invention is a modulator according to the above, for use in the treatment of cystic fibrosis wherein it has effect on CFTR-dependent ion transport across cellular membrane and/or it has the ability to increase the number of mutant CFTR proteins that reach the cell surface.

[0024] Preferably, for use in the treatment of cystic fibrosis wherein it has stabilizing effect on the structure of the mutant CFTR protein and/or blocks the interaction with cellular proteins responsible for the premature degradation of mutant CFTR

50 [0025] Preferably, for use in the treatment of cystic fibrosis wherein it has effect on mutant CFTR protein, wherein said CFTR mutation is a mutation  $\Delta F508$ -CFTR, or another mutation of class II.

[0026] The present invention is illustrated in the accompanying drawings where:

**Figure 1**

55 The effects of different compounds on iodide efflux at  $1\mu M$  in  $\Delta F508$ -CFTR HeLa cells. (a) bar graph showing the peak amplitudes of Fsk/Gsk dependent iodide effluxes in cells treated by the different drugs as in A. Values are mean of 3 independent experiments.  $*p < 0.05,$   $**p < 0.01.$  (b) chemical structures of active correctors identified *in silico* (c) examples of iodide efflux curves obtained in HeLa cells stably transfected with  $\Delta F508$ -CFTR and treated for 24 hours with  $10\mu M$  with different compounds. CFTR dependent response was induced by  $10\mu M$  Forskolin (Fsk)

+ 30 $\mu$ M Genistein (Gsk) as indicated by the horizontal bar above the traces. **(d)** EC50 was determined for active compounds of pocket 2: 407882 and 73100 and one of pocket 1: 130813, for 118208 EC50 could not be precisely determined since the maximum of iodide efflux was not reached even at 100 $\mu$ M (also shown).

5 **Figure 2**

To test whether the compounds exhibit potentiator activity independent of their effect on CFTR trafficking, we examined iodide efflux in untreated WT-CFTR HeLa cells. Compounds were added along with forskolin and their effects were compared to that of Forskolin alone or forskolin plus genistein. Unlike genistein, all tested molecules induced an I<sup>-</sup> efflux greater than that of forskolin alone.

10

**Figure 3**

Potentialiation was also tested in  $\Delta$ F508-CFTR HeLa cells treated for 2 hours with miglustat to rescue  $\Delta$ F508-CFTR. I<sup>-</sup> efflux was stimulated either with forskolin alone, with forskolin plus genistein or forskolin plus the different compounds. As shown in figure, only genistein was able to increase efflux, demonstrating the absence of potentialiation activity by our drugs.

15

**Figure 4**

Impact of identified correctors on  $\Delta$ F508-CFTR maturation and cell localization.

20

**(a)** Effects of different compounds on CFTR processing. Representative immunoblots of WT-CFTR and  $\Delta$ F508-CFTR proteins of the proteins from HeLa cells treated with 1  $\mu$ M of the different compounds for 24 hours with Mab 24-1. The positions of the mature (band C) and immature (band B) forms of CFTR are indicated.

**(b)** Comparison of relative intensity (C/B+C) for WT-CFTR,  $\Delta$ F508-CFTR alone and  $\Delta$ F508-CFTR after correction with our molecules.

25

**(c)** Effects of the different compounds used at 1  $\mu$ M on CFTR localization. Confocal imaging showing the plasma membrane localisation of WT-CFTR and intracellular localisation of  $\Delta$ F508-CFTR. The effect of drugs is illustrated in panels c to f. Bars: 20 $\mu$ M. Arrows indicate staining of CFTR at the plasma membrane.

**Figure 5**

30

Synergistic effect of active compounds on iodide efflux tested at 1  $\mu$ M.

**(a)** Iodide efflux in response to 1 $\mu$ M Forskolin (Fsk) + 30  $\mu$ M Genistein (Gsk) as indicated by the horizontal bar above the traces, for cells treated for 24h with a tested compounds alone and in combination as follows **(a)** 407882, 118208, **(b)** 118208, 73100 **(c)** 407882, 37173. **(d)** bar graph showing the peak amplitudes of Fsk/Gst dependent iodide effluxes in cells treated by the different drugs as in . Values are mean of 3 independent experiments. \*p<0.05, \*\*p<0.01

35

**Figure 6**

40

**(a)/(b)** Current-voltage relationship for cAMP-dependent chloride currents in HeLa cells treated with 407882(12) plus 118208(6) compounds at 1 $\mu$ M.

**Figure 7**

45

The effects of different compounds on iodide efflux at 1 $\mu$ M in an epithelial serous cell line derived from a  $\Delta$ F508 CF patient (CF-4KM) cells. The concentration-dependence has been shown for the most potent molecule 407882

**[0027]** For a better understanding of the invention the examples of the inventive subject matter are disclosed below.

**Examples**

50

**Materials and Methods**

**Antibodies**

55

**[0028]** The following antibodies were used: MAB25031 (clone 24-1, R&D systems, USA) and MM13-4 (Upstate,) monoclonal antibodies (mAb) for CFTR detection; Fluorescent secondary antibodies Alexa 594 and 488 were purchased from Molecular Probes (Cergy Pontoise, France)

**Cell culture**

**[0029]** Stably transfected HeLa cells (with pTracer plasmid alone as a control (pTracer) or expressing WT-CFTR (spTCF-WT),  $\Delta$ F508-CFTR s(pTCF-F508del) were provided by Pascale Fanen (Inserm U.468, Créteil, France) and grown as described elsewhere(16). Briefly, HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin and 250  $\mu$ g/ml zeocin. Cultures were done at 37°C in a humidified incubator with 5% CO<sub>2</sub>. The expression of WT-CFTR and  $\Delta$ F508-CFTR in these cells was verified by immunoprecipitation and immunocytochemistry all along the study. Treatments with different molecules (at 1 and 10  $\mu$ M) and vehicle were done when cells reached 75% confluence.

**[0030]** CF-KM4 cell line, obtained by transformation of primary cultures of CF tracheal gland serous cells homozygous for the  $\Delta$ F508 mutation by using the wild-type SV40 virus, were grown as described elsewhere(17).

**Immunoblot experiments**

**[0031]** Cells cultured in 75 cm<sup>2</sup> flasks were washed twice with ice cold PBS, scraped in 2ml PBS and centrifuged at 600g for 5 min. The pellets were suspended in 300 $\mu$ l RIPA buffer (50 mM Tris-HCl, 150mM NaCl, 1% TritonX-100, 1% Na deoxycholate, 0.1% SDS, pH 7.5) at 4°C for 30 min with agitation After centrifugation at 15000g for 30 min the supernatants were processed for immunoblot experiments as previously described (18) with slight modifications.

**[0032]** The samples were resolved by 8% SDS-PAGE, transferred onto PVDF membranes and analysis was performed following manufacturer's recommendations for the Odyssey infrared imaging system (LI-COR Biosciences, NE, USA). Blot membranes were blocked with Odyssey buffer (ScienceTec, Paris, France) for 1 hour and hybridized using monoclonal anti CFTR Mab24-1 (1/1000). The proteins were visualized by incubation with secondary antibodies (1/10000) and detected using ECL technique(19)

**Immunofluorescence Staining**

**[0033]** HeLa cells grown on glass coverslips were treated as above and as described in Lipecka et al(20). Cells were fixed with 4% formaldehyde and permeabilized with 0.1% Triton in PBS. Cells were blocked with 1% bovine serum albumine in PBS/Triton and incubated at 4°C overnight with the primary antibodies, 24-1 (1:300). After washing and blocking with 5% normal goat serum, cells were incubated with the secondary antibodies. Glass coverslips were mounted using the Vectashield mounting medium (Vector laboratories) and examined by confocal laser microscopy (Zeiss, LSM 510).

**Iodide efflux experiments**

**[0034]** CFTR chloride channel activity was assayed by measuring iodide(<sup>125</sup>I) efflux from transfected CHO cells as described previously(21). Cells grown for 4 days in 96-well plates were washed twice with 2 ml of modified Earle's salt solution containing 137 mM NaCl, 5.36 mM KCl, 0.4 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.8 mM MgCl<sub>2</sub>, 1.8 mM CaCl<sub>2</sub>, 5.5 mM glucose, and 10 mM HEPES, pH 7.4. Cells were then incubated in the same medium containing 1mM KI (1 mCi of Na<sup>125</sup>I/ml, NEN Life Science Products) for 30 min at 37 °C. After washing, cells were incubated with 1 ml of modified Earle's salt solution. After 1 min, the medium was removed to be counted and was quickly replaced by 1 ml of the same medium. This procedure was repeated every 1 min for 8 min. The first three aliquots were used to establish a stable baseline in efflux buffer alone. Medium containing cocktail aiming to increase intracellular cAMP 10 $\mu$ M forskolin and 30 $\mu$ M genistein) was used for next aliquots in order to activate CFTR chloride channels. At the end of the incubation, the medium was recovered, and cells were solubilized in 1 N NaOH. The radioactivity was determined using a g-counter (LKB). The total amount of <sup>125</sup>I (in cpm) at time 0 was calculated as the sum of cpm counted in each 1-min sample plus the cpm in the NaOH fraction. The fraction of initial intracellular <sup>125</sup>I lost during each time point was determined, and time-dependent rates of <sup>125</sup>I efflux were calculated according to Becq *et al.* (22) from

$$\ln(^{125}\text{I}_{t_1}/^{125}\text{I}_{t_2})/(t_1 - t_2),$$

where

<sup>125</sup>I<sub>t</sub> is the intracellular <sup>125</sup>I at time *t*;

and *t*<sub>1</sub> and *t*<sub>2</sub> are successive time points.

**[0035]** Curves were constructed by plotting rate of <sup>125</sup>I efflux *versus* time. Data are presented as the mean  $\pm$  S.E. of *n* separate experiments.

[0036] Differences were considered statistically significant using the Student's *t* test when the *p* value was less than 0.05.

### Whole cell patch-clamp recordings

[0037] Technique for patch-clamp recordings in the whole cell configuration has been described elsewhere(23,24). Stably transfected cells were plated in 35 mm cell culture plastic Petri dishes that were mounted on the stage of an inverted microscope. Patch-clamp experiments were performed at room temperature with an Axopatch 200A amplifier controlled by a computer *via* a digitdata 1440 interface (Axon Instruments, USA). Pipettes were pulled from hard glass (Kimax 51) using a Setter micropipette puller and their tip was fire-polished. Current recordings were performed using the nystatin-perforated patch clamp configuration. Nystatin stock solution (50 mg/ml) was prepared daily in DMSO. The stock solution was diluted (1:250) in the internal solution which was then sonicated during 1 minute. The internal solution contained the following (in mM):, 131 NaCl, 2 MgCl<sub>2</sub>, and 10 Hepes-Na<sup>+</sup>, pH 7.3, adjusted with NaOH. The bath solution contained (in mM): 150 NaCl, 1 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 35 sucrose and 10 Hepes-Na<sup>+</sup>, pH 7.3, adjusted with NaOH.

[0038] Currents were recorded by application of regular voltage pulses of 60 mV amplitude during 1 second, from a holding potential of 0 mV, with an interval of 3 seconds.

[0039] To establish I-V curves, regular voltage pulses were interrupted by series of 9 voltage jumps (1-s duration each), toward membrane potentials between -100 and +80 mV. CFTR Cl<sup>-</sup> currents were activated with 200 μM 8-(4-chlorophenylthio)-cAMP sodium salt (CPT-cAMP) plus 100 μM 3-isobutyl-1-methylxanthine (IBMX).

[0040] When maximal stimulation was reached, cells were bathed with 5 μM of the specific CFTRinhibitor, CFTR<sub>inh</sub>-172, added to the CPT-cAMP solution. CFTR-currents were defined as the differences in current amplitudes recorded during maximum stimulation by CPT-cAMP and after inhibition by CFTR<sub>inh</sub>-172.

### Nasal Potential Difference (NPD) measurements

[0041] The method for nasal potential measurement was adapted and miniaturised from the technique developed by us for young children(25). Mice were anesthetized by an intraperitoneal injection of ketamine (133 mg/kg ; IMALGENE 1000, MERIAL, France) and xylazine (13.3 mg/kg ; Rompun 2%, BayerPharma, France). Mice were positioned on a 45° tilt board and a paper pad was placed under the nose to avoid mice quelling. A subcutaneous needle was connected to an Ag<sup>+</sup>/AgCl reference electrode by an agar bridge. A double-lumen polyethylene catheter (0.5mm diameter) was inserted into one nostril 4mm depth. One lumen perfused by a Ringer solution (in mM: 140 NaCl, 6 KCl, 10 Hepes, 10 Glucose, 1 MgCl<sub>2</sub>, 2 CaCl<sub>2</sub>, pH adjusted to 7,4 with NaOH) at 0,15 mL/h is connected to a measuring Ag<sup>+</sup>/AgCl electrode. The two Ag<sup>+</sup>/AgCl electrodes were connected to a high-impedance voltmeter (LOGAN research Ltd, United Kingdom). The second lumen perfused solution with the following sequence : (1) Ringer solution, (2) Ringer solution containing amiloride (inhibitor of Na<sup>+</sup> conductance, 100 μM), (3) Low Chloride Ringer solution, to unmask Cl<sup>-</sup> conductances (in mM: 140 Na gluconate, 6 K gluconate, 10 Hepes, 10 Glucose, 1 MgCl<sub>2</sub>, 6 Ca-gluconate, pH adjusted to 7,4 with NaOH), (4) Low Chloride Ringer solution containing CFTR inhibitor-172 (5 μM, Calbiochem, Germany) to evaluate the participation of CFTR. Each solution was perfused at least 3 minutes, and 30 seconds stability was required before perfusion switch. Steady state transepithelial potential,  $V_{TE}$ ,  $\Delta V_{TEAmil}$  (difference between  $V_{TE}$  and transepithelial potential recorded after perfusion of amiloride-containing solution),  $\Delta V_{TEamilLowCl}$  (difference between  $V_{TE}$  and transepithelial potential recorded after perfusion with Low Cl<sup>-</sup> plus amiloride-containing solution) and  $\Delta V_{TEamilLowClInh-172}$  (difference between  $V_{TE}$  and after addition of CFTR inhibitor to the previous solution) were the means of 30 values recorded during stability.

### MTT cell viability assay(26)





[0042] To determine cell viability the typical MTT assay was used. HeLa cells were cultured in a 96-well plate and exposed to varying concentrations of compounds of the invention for 24 h. After washing, MTT solution and medium were then introduced. After incubation; the resultant formazan crystals were dissolved in dimethyl sulfoxide and the absorbance intensity measured by a microplate reader at 570 nm.

[0043] Yellow MTT is reduced to purple formazan in living cells. The absorbance of this colored solution can be quantified by measuring at a certain wavelength by a spectrophotometer. This conversion can be directly related to the number of viable (living) cells.

### Virtual Screening - Identification of Modulator Compounds

[0044] A database of a low molecular weight compounds was used in the virtual screening process as a source of hits. Molecular docking program Dock 6.1 was used to test a conformational space of small molecules inside two potential binding sites on the protein surface. Subsequently, all selected ligands and whole complexes were fully minimized in

force field. At each step, a set of scoring functions was used for rating of potential complexes and appropriate molecules were selected for experimental tests.

5		118208/NOP1.6/Pok 1c
10		2-[(3-nitrophenyl)methylsulfanyl]-3,7-dihydropurin-6-one
15		407882/NOP2.6/Pok 2f
20		2-[hydroxy(phenyl)phosphoryl]ethyl-phenylphosphinic acid
25		130813/NOP1.2/Pok1b
30		4-((6-chloro-2-methoxy-9-acridinyl)amino)-2-((4-methyl-1-piperazinyl)methyl)phenol
35		73100/Pok2e
40		2-(9H-fluoren-2-ylcarbamoyl)terephthalic acid

## Results

### Effect of drugs on iodide, I<sup>-</sup>, efflux

**[0045]** To test drug correction of  $\Delta F508$ -CFTR trafficking and function we evaluated halide permeability by a macroscopic assay using a robotic cell-based methodology using the I<sup>-</sup> efflux technique. In the first series of experiments, the potential corrector effects were tested by 24 hour pre-treatment of  $\Delta F508$ -CFTR HeLa cells with all compounds at 1  $\mu$ M followed by measurements of cAMP-dependent radiolabel iodide efflux. Treatments with compounds 130813 and 118208 on pocket 1 and 73100 and 407882 on pocket 2, lead to significant increase of cAMP-stimulated radiolabel iodide efflux (**Fig. 1a**), the most potent being 407882. At this low dose (1  $\mu$ M) the increase in the cAMP-stimulated efflux was lower than that observed using 100  $\mu$ M of the known corrector miglustat(27). Examples of I<sup>-</sup> efflux stimulation after treatment with each of the four active compounds are illustrated in **Figure 1b**. cAMP-stimulated I<sup>-</sup> efflux was completely prevented when experiments were performed in the presence of the CFTR channel blocker CFTR<sub>inh</sub>-172.

**[0046]** We further tested the effect of the four compounds in a wide range of concentrations and determined EC<sub>50</sub> for pocket 1 compound 130813, and two pocket 2 compounds 407882 and 73100 at 1  $\mu$ M, 10  $\mu$ M and 844 nM, respectively (**Fig. 1c**). The EC<sub>50</sub> for pocket 1 - 118208 could not be precisely determined since the maximum iodide efflux was not

reached even at 100 $\mu$ M (**Fig. 1d**). Notably, the effect of compound 407882 could be increased by 3-fold when used at 10 $\mu$ M, reaching a stimulated efflux comparable to the value observed for WT-CFTR (**Fig. 2**).

**[0047]** To test whether the compounds exhibit potentiator activity independent of their effect on CFTR trafficking, we examined iodide efflux in untreated WT-CFTR HeLa cells. Compounds were added along with forskolin and their effects were compared to that of forskolin alone or forskolin plus genistein. Unlike genistein, all tested molecules induced an I<sup>-</sup> efflux greater than that of forskolin alone (**Fig. 2**). Potentiation was also tested in  $\Delta$ F508-CFTR HeLa cells treated for 2 hours with miglustat to rescue  $\Delta$ F508-CFTR. I<sup>-</sup> efflux was stimulated either with forskolin alone, with forskolin plus genistein or forskolin plus the different compounds. As shown in **Figure 3**, only genistein was able to increase efflux, demonstrating the absence of potentiation activity by our drugs.

#### Effect of drugs on CFTR maturation

**[0048]** The efficacy of the four compounds as correctors for  $\Delta$ F508-CFTR trafficking was further validated by immunoblotting. We assumed that detection of a fully glycosylated band C suggests correct processing of  $\Delta$ F508-CFTR. A representative immunoblot is shown in **Figure 4a**. Anti-CFTR antibodies detect two bands in proteins derived from WT-CFTR cells, (line WT-CFTR in **Fig 4a**). The diffuse band of approximately 170kDa (band C) corresponds to a mature, fully glycosylated protein that has processed through the Golgi apparatus. The band below of about 145kDa corresponds to the immature core-glycosylated protein located in the endoplasmic reticulum. In  $\Delta$ F508-CFTR expressing cells, only the immature protein is detectable (line  $\Delta$ F508 in **Fig 4a**). Band C was clearly detectable in cells treated with 1 $\mu$ M of compound 407882 as compared to untreated cells, whereas the signal at 170kDa was not different from DMSO treatment in cells treated with 1 $\mu$ M of compounds 118208, or 130813 or very slightly increased in cells treated by 1 $\mu$ M of compound 73100. None of the compounds modified total protein expression. The relative abundance of mature CFTR, expressed as the ratio of band C to band C+band B is shown in **Figure 4b**. Only compound 407882 increased significantly the relative abundance of mature CFTR.

#### Effect of drugs on CFTR immunolocalization

**[0049]** **Figure 4c** shows typical CFTR staining at the plasma membrane in WT-CFTR expressing HeLa cells whereas  $\Delta$ F508-CFTR was found throughout the cytoplasm. Treatment of cells for 24 hours with 1 $\mu$ M of 407882 resulted in a clear CFTR staining at or near the plasma membrane, indicating rescue of  $\Delta$ F508-CFTR trafficking in agreement with immunoblot experiments. When cells were treated by each of the three other compounds, 118208, 73100 or 130813, a discrete punctuate staining at the plasma membrane was observed in a small fraction of cells, as illustrated for compound 118208 in **Figure 4c**.

#### Combined effect of compounds binding to different pockets.

**[0050]** If two compounds are able to correct  $\Delta$ F508-CFTR by binding to the same protein conformation but at different surface cavities their effects could be additive or synergistic. We tested this hypothesis by two independent types of assays, namely iodide efflux and patch clamp. The results from iodide permeability tests (**Fig. 5**) showed that combined treatment of cells with compounds 118208 plus 407882 (**Fig. 5a**) or with 118208 plus 73100 (**Fig. 5b**) at 1 $\mu$ M of each, leads to greater cAMP-dependent anion fluxes than those observed with any of the molecules alone. In this series of experiments the compound 37173 (**Fig. 5c**) was used as a control as it did not induce any cAMP-stimulated iodide efflux at the same concentration. As shown in **Figure 5c**, co-treatment of  $\Delta$ F508-CFTR HeLa cells with 37173 plus 407882 induced cAMP-stimulated iodide efflux with an amplitude similar to 407882 treatment alone. By contrast, co-treatment with compounds 118208 and 407882 induced iodide efflux with an amplitude equal to the sum of effluxes induced by each compound, whereas a slight synergistic effect was observed after treatment by 118208 plus 73100.

**[0051]** The activity of the different compounds was also evaluated in patch-clamp experiments. **Figure 6a** summarizes the mean values of current amplitudes recorded at -60mV in the different experimental conditions. CFTR-related current density ( $I_{\Delta$ F508-CFTR}; pA/pF) is defined as cAMP-stimulated current minus the current recorded after inhibition by CFTR inh-172 at 5 $\mu$ M, and normalized to cell capacitance.  $I_{\Delta$ F508-CFTR was very low in untreated cells and stimulated by around 3-fold when cells were cultured at 27°C for 24 hours before recordings. Treatment of cells for 24h with 1 $\mu$ M of either 118208, 407882 or 73100 alone, did not increase current amplitude-as compared to their respective controls (data not shown). However, 24h pre-treatment with 1 $\mu$ M of 118208 plus 407882 or 118208 plus 73100 showed a significant increase in  $I_{\Delta$ F508-CFTR. Examples of linear I/V plots from cells pretreated by 118208 plus 407882 before stimulation, in the presence of cptcAMP+IBMX and after inhibition by CFTRinh-172 are shown in **Figure 6b**.

**Effects of 407882 and 118208 on CF-4KM cells**

**[0052]** The effects of the four molecules active in HeLa cells were next tested on CFTR-dependent iodide efflux in an epithelial serous cell line derived from a  $\Delta F508$  CF patient (CF-KM4) expressing low amounts of endogenous  $\Delta F508$ -CFTR. In these epithelial cells compounds 407882 and 118208 were still able to induce significant cAMP-dependent iodide efflux (**Fig. 7**). However, it must be noted that 2 molecules correcting  $\Delta F508$ -CFTR in HeLa cells (130813 and 73100) were not active in this cell line.

**Effects of 73100 plus 118208 on nasal potential difference in  $\Delta F508$  mice.**

**[0053]** Our results in cells suggested that the pairs of molecules acting on different pockets display additive correcting effects. To test if these molecules are active *in vivo*, nasal potential difference ( $\Delta V_{TE}$ ) was monitored (25) in  $\Delta F508$  /  $\Delta F508$  mice treated intranasally for 24 hours with 30  $\mu$ l of 73100 plus 118208 molecules (0.1  $\mu$ mol each) embedded in liposomes (5:1) or with liposomes alone. In  $\Delta F508$  mice, basal  $V_{TE}$  values and  $\Delta V_{TE}$  changes induced by perfusion of nasal epithelium with 100  $\mu$ M amiloride,  $\Delta V_{TE_{amil}}$  were similar in mice treated with the two molecules or with liposomes alone. By contrast, perfusion of low Cl<sup>-</sup> solution in 3 out of 5 mice hyperpolarized  $V_{TE}$  by more than 2 mV ( $\Delta V_{TE_{amil-LowCl}}$ ) i.e. the threshold value established by us as significant effect of treatment (manuscript in preparation). The CFTR-related current unmasked by CFTR inhibitor  $I_{inh172}$  represents about 30% of ( $\Delta V_{TE_{amil-LowCl}}$ ) (data not shown).

**References****[0054]**

- Ollero M, Brouillard F, Edelman A. Cystic fibrosis enters the proteomics scene: new answers to old questions. *Proteomics*, 2006 Jul;6(14):4084-99.
- Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*, 1989 Sep 8;245(4922):1066-73.
- Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science*, 1989 Sep 8;245(4922): 1059-65.
- Castellani C, Cuppens H, Macek M, Jr., Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros*, 2008 May;7(3): 179-96.
- Cystic Fibrosis Mutation Database <http://www.genet.sickkids.on.ca/cftr/app>.
- Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Celi*, 1993 Jul 2;73(7): 1251-4.
- Wilschanski M, Zielenski J, Markiewicz D, Tsui LC, Corey M, Levison H, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. *J Pediatr*, 1995 Nov;127(5):705-10.
- Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell*, 1995 Oct 6;83(1):121-7.
- Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. *Hum Mutat*, 2002 Jun;19(6):575-606.
- Lewis HA, Zhao X, Wang C, Sauder JM, Rooney I, Noland BW, et al. Impact of the  $\Delta F508$  mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. *J Biol Chem*, 2005 Jan 14;280(2): 1346-53.
- Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. *Physiol Rev*, 1999 Jan;79(1 Suppl):S145-66.
- Reddy MM, Light MJ, Cjuinton PM. Activation of the epithelial Na<sup>+</sup> channel (ENaC) requires CFTR Cl<sup>-</sup> channel function. *Nature*, 1999 Nov 18;402(6759):301-4.
- Ahmed N, Corey M, Forstner G, Zielenski J, Tsui LC, Ellis L, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. *Gut*, 2003 Aug;52(8): 1159-64.
- Riordan JR. Assembly of functional CFTR chloride channels. *Annu Rev Physiol*, 2005;67:701-18.
- Allen MP, Tildesley DJ. Computer simulation of liquids: Oxford, Clarendon Press; 1987.
- Jungas, T., et al., Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator. *J Biol Chem*, 2002. 277(31): p. 27912-8.
- Antigny, F. et al. Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of  $\Delta F508$ -CFTR. *Cell calcium* 43, 175-83(2008).
- Baudouin-Legros, M. et al. Control of basal CFTR gene expression by bicarbonate-sensitive adenylyl cyclase in human pulmonary cells. *Cellular physiology and biochemistry : international journal of experimental cellular phys-*

iology, biochemistry, and pharmacology 21, 75-86(2008).

19. Bensalem, N. et al. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. *Molecular & cellular proteomics* : MCP 4, 1591-601(2005).

20. Lipecka, J. et al. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. *American journal of physiology. Cell physiology* 282, C805-16(2002).

21. Marivingt-Mounir, C, et al., Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. *J Med Chem*, 2004. 47(4): p. 962-72.

22. Becq, F., et al., Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. *J Biol Chem*, 1999. 274(39): p. 27415-25.

23. Hinzpeter, A. et al. Association between Hsp90 and the ClC-2 chloride channel upregulates channel function. *American journal of physiology. Cell physiology* 290, C45-56(2006).

24. Tanguy, G. et al. CSN5 binds to misfolded CFTR and promotes its degradation. *Biochimica et biophysica acta* 1783, 1189-99(2008).


25. Sermet-Gaudelus, I. et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. *Thorax* 65, 539-44(2010).

26. Norez, C. et al. Maintaining low Ca<sup>2+</sup> level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. *Traffic (Copenhagen, Denmark)* 7, 562-73(2006).

27. Norez, C. et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. *FEBS letters* 580, 2081-6(2006).

## Claims

1. A compound of general formula (I):




its tautomers, E and Z geometrical isomers, optically active forms such as enantiomers, diastereomers and their racemate forms or a mixture of stereoisomeric forms or its pharmaceutically acceptable salts thereof or complexes thereof; wherein Z<sup>1</sup> is independently selected from the group consisting of:

-C<sub>n</sub>H<sub>(2n)</sub><sup>-</sup>, which is branched or unbranched wherein n is an integer from 1 to 5; -C<sub>n</sub>H<sub>(2n-2)</sub><sup>-</sup> in E or Z geometrical conformation which is branched or unbranched wherein n is an integer from 2 to 5; -C<sub>n</sub>H<sub>(2n-4)</sub><sup>-</sup> which is branched or unbranched wherein n is an integer from 2 to 5; -CR'H-, -C<sub>2</sub>H<sub>3</sub>R'-, E or Z -C<sub>2</sub>HR'-, -C<sub>3</sub>H<sub>5</sub>R'-, E or Z -C<sub>3</sub>H<sub>3</sub>R'-, -OCH<sub>2</sub>-, -CH<sub>2</sub>O-, -NR"CH<sub>2</sub>-, -CH<sub>2</sub>NR"-; wherein R' is independently selected from the group consisting of: -H, halogen, -NH<sub>2</sub>, -OH, -CN, CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -SH, -SCN, -CH<sub>3</sub>-, -C<sub>2</sub>H<sub>5</sub>; wherein R" is independently selected from the group consisting of: -H, -CH<sub>3</sub>-, -C<sub>2</sub>H<sub>5</sub>; wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group consisting of aromatic ring or heteroaromatic ring,

as a modulator of a mutant CFTR protein for use in the treatment of cystic fibrosis.

2. A compound for use according to claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from the group of sub-formula (Ia):



10 wherein  $A_1, A_2, A_3, A_4, A_5, A_6$  is independently selected N or C atoms wherein ring contain 0-3 nitrogen atoms;  
 wherein  $E^1, E^2, E^3, E^4, E^5$  represents optional substituents, which are selected from:  $-OR_B, -OC(=O)R_C,$   
 $-OC(=O)OR_B, -OC(=O)N(R_A)R_{A'}, -C(=O)R_C, -C(=O)N(R_A)R_{A'}, -C(=O)N(OR_B)R_A, -C(=O)OR_B, -C(=S)R_C,$   
 $-C(=O)C(=O)R_C, -CH_2OR_B, -CH_2CH_2OR_B, -CH_2N(R_A)R_{A'}, -CH_2CH_2N(R_A)R_{A'}, -CH_2OCH_2R_C, -CH_2N(R_A)CH_2R_C,$   
 $-SR_D, -S(=O)R_D, -SO_2R_D, -SO_2N(R_A)R_{A'}, -SO_3R_B, -N(R_A)C(=O)R_C, -N(R_A)C(=O)OR_B, -N(R_A)C(=O)N(R_{A'})R_{A'"},$   
 $-N(R_{A'})SO_2R_D, -N(R_{A'})SO_2N(R_{A'})R_{A'"}, -N(R_{A'})R_{A'}, -N(R_{A'})C(=O)R_C, -N(R_{A'})C(=O)OR_B, -N(R_{A'})N(R_{A'})R_{A'"},$   
 $-N(R_{A'})N(R_{A'})C(=O)R_C, -NO_2, -CN, -CF_3, -CHF_2, -CH_2F, NH_2, -SCN, -SO_2CN, -F, Cl, -Br, -I, -PO_3H_2, -OPO_3H_2,$   
 $-C_nH_{2n}R_C$  which is branched or unbranched wherein n is an integer from 1 to 5;  $-C_nH_{(2n-2)}R_C$  in E or Z geometrical  
 15 conformation which branched or unbranched wherein n is an integer from 2 to 5;  $-C_nH_{(2n-4)}R_C$  which is branched  
 or unbranched wherein n is an integer from 2 to 5;


20 wherein  $R_A, R_{A'}, R_{A''}$  are each independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3,$   
 $-CHF_2, -CH_2F, -OH;$

wherein  $R_B$  is independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3, -CHF_2, -CH_2F,$   
 $-CH_2Cl, -CH_2Br, -CH_2I;$

wherein  $R_C$  is independently selected from the group consisting of:  $-H,$  lower alkyl group,  $-CN, -CF_3, -CHF_2, -CH_2F,$   
 $-CH_2Cl, -CH_2Br, -CH_2I, -F, -Cl, -Br, -I, -NH_2,$

25 wherein  $R_D$  is independently selected from the group consisting of:  $-H,$  lower alkyl group;

3. A compound for use according to claim 1 or 2, said compound being represented by the following structures:



- 40 4. A compound for use according to claim 1 or 2 or 3, wherein it has effect on mutant CFTR protein, wherein said  
 CFTR mutation is a mutation  $\Delta F508$ -CFTR, or another mutation of class II and where a mutation  $\Delta F508$ -CFTR, or  
 another mutation of class II are involved in CFTR protein malfunction.

- 45 5. A compound for use according to claim 4, wherein the disease associated with CFTR protein malfunction is cystic  
 fibrosis.


- 50 6. Modulator of formula (I) according to claim 1, for use in the treatment of cystic fibrosis wherein it has effect on CFTR-  
 dependent ion transport across cellular membrane and/or it has the ability to increase the number of mutant CFTR  
 proteins that reach the cell surface.

7. Modulator of formula (I) according to claim 1, for use in the treatment of cystic fibrosis wherein it has stabilizing  
 effect on the structure of the mutant CFTR protein and/or blocks the interaction with cellular proteins responsible  
 for the premature degradation of mutant CFTR

- 55 8. Modulator of formula (I) according to claim 1, for use in the treatment of cystic fibrosis wherein it has effect on mutant  
 CFTR protein, wherein said CFTR mutation is a mutation  $\Delta F508$ -CFTR, or another mutation of class II.

Patentansprüche

1. Verbindung der allgemeinen Formel (I):




ihre Tautomere, E- und Z-geometrischen Isomeren, optisch aktiven Formen wie Enantiomere, Diastereomere und ihre Racematformen oder ein Gemisch stereoisomerer Formen, oder pharmazeutisch verträgliche Salze davon oder Komplexe davon; wobei Z<sup>1</sup> unabhängig aus der Gruppe ausgewählt ist, bestehend aus:

-C<sub>n</sub>H<sub>(2n)</sub>-, die verzweigt oder unverzweigt ist, wobei n eine ganze Zahl von 1 bis 5 ist; -C<sub>n</sub>H<sub>(2n-2)</sub>- in E- oder Z-geometrische Konformation, die verzweigt oder unverzweigt ist, wobei n eine ganze Zahl von 2 bis 5 ist; -C<sub>n</sub>H<sub>(2n-4)</sub>- die verzweigt oder unverzweigt ist, wobei n eine ganze Zahl von 2 bis 5 ist; -CR'H-, -C<sub>2</sub>H<sub>3</sub>R'-, E oder Z -C<sub>2</sub>HR'-, -C<sub>3</sub>H<sub>5</sub>R'-, E oder Z -C<sub>3</sub>H<sub>3</sub>R'-, -OCH<sub>2</sub>-, -CH<sub>2</sub>O-, -NR"CH<sub>2</sub>-, -CH<sub>2</sub>NR"-; wobei R' unabhängig aus der Gruppe ausgewählt ist, bestehend aus: -H, Halogen, -NH<sub>2</sub>, -OH, -CN, CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -SH, -SCN, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>; wobei R" unabhängig aus der Gruppe ausgewählt ist, bestehend aus: -H, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>; wobei R<sup>1</sup> und R<sup>2</sup> unabhängig aus der Gruppe ausgewählt sind, bestehend aus einen aromatischen Ring oder einen heteroaromatischen Ring,

als Modulator eines mutierten CFTR-Proteins zur Verwendung bei der Behandlung von zystischer Fibrose.

2. Verbindung zur Verwendung nach Anspruch 1, wobei R<sup>1</sup> und R<sup>2</sup> unabhängig aus der Gruppe der Unterformel (Ia) ausgewählt sind:



wobei A<sub>1</sub>, A<sub>2</sub>, A<sub>3</sub>, A<sub>4</sub>, A<sub>5</sub>, A<sub>6</sub> unabhängig aus N oder C-Atomen ausgewählt ist, wobei der Ring 0-3 Stickstoffatomen enthält;

wobei E<sup>1</sup>, E<sup>2</sup>, E<sup>3</sup>, E<sup>4</sup>, E<sup>5</sup> steht gegebenenfalls für Substituenten, die ausgewählt sind aus: -OR<sub>B</sub>, -OC(=O)R<sub>C</sub>, -OC(=O)OR<sub>B</sub>, -OC(=O)N(R<sub>A</sub>)R<sub>A</sub>' , -C(=O)R<sub>C</sub>, -C(=O)N(R<sub>A</sub>)R<sub>A</sub>' , -C(=O)N(OR<sub>B</sub>)R<sub>A</sub>' , -C(=O)OR<sub>B</sub>, -C(=S)R<sub>C</sub>, -C(=O)C(=O)R<sub>C</sub>, -CH<sub>2</sub>OR<sub>B</sub>, -CH<sub>2</sub>CH<sub>2</sub>OR<sub>B</sub>, -CH<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>' -CH<sub>2</sub>CH<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>' , -CH<sub>2</sub>OCH<sub>2</sub>R<sub>C</sub>, -CH<sub>2</sub>N(R<sub>A</sub>)CH<sub>2</sub>R<sub>C</sub>, -SR<sub>D</sub>, -S(=O)R<sub>D</sub>, -SO<sub>2</sub>R<sub>D</sub>, -SO<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>' , -SO<sub>3</sub>R<sub>B</sub>, -N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -N(R<sub>A</sub>)C(=O)OR<sub>B</sub>, -N(R<sub>A</sub>)C(=O)N(R<sub>A</sub>)R<sub>A</sub>' , -N(R<sub>A</sub>)SO<sub>2</sub>R<sub>D</sub>, -N(R<sub>A</sub>)SO<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>' , -N(R<sub>A</sub>)R<sub>A</sub>' , -N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -N(R<sub>A</sub>)C(=O)OR<sub>B</sub>, -N(R<sub>A</sub>)N(R<sub>A</sub>)R<sub>A</sub>' , -N(R<sub>A</sub>)N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -NO<sub>2</sub>, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -NH<sub>2</sub>, -SCN, -SO<sub>2</sub>CN, -F, Cl, -Br, -I, -PO<sub>3</sub>H<sub>2</sub>, -OPO<sub>3</sub>H<sub>2</sub>, -C<sub>n</sub>H<sub>2n</sub>R<sub>C</sub> die verzweigt oder unverzweigt ist, wobei n eine ganze Zahl von 1 bis 5 ist; -C<sub>n</sub>H<sub>(2n-2)</sub>R<sub>C</sub> in E- oder Z-geometrische Konformation, die verzweigt oder unverzweigt, wobei n eine ganze Zahl von 2 bis 5 ist; -C<sub>n</sub>H<sub>(2n-4)</sub>R<sub>C</sub> die verzweigt oder unverzweigt ist, wobei n eine ganze Zahl von 2 bis 5 ist;

wobei R<sub>A</sub>, R<sub>A</sub>' , R<sub>A</sub>" jeweils unabhängig aus der Gruppe ausgewählt sind, bestehend aus: -H, Niederalkylgruppe, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OH;


wobei R<sub>B</sub> unabhängig aus der Gruppe ausgewählt ist, bestehend aus: -H, Niederalkylgruppe, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -CH<sub>2</sub>C1, -CH<sub>2</sub>Br, -CH<sub>2</sub>I;

wobei R<sub>C</sub> unabhängig ausgewählt ist aus der Gruppe bestehend aus: -H, Niederalkylgruppe, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -CH<sub>2</sub>C1 , -CH<sub>2</sub>Br, -CH<sub>2</sub>I, -F, -Cl, -Br, -I, -NH<sub>2</sub>;

wobei R<sub>D</sub> unabhängig aus der Gruppe ausgewählt ist, bestehend aus: -H, Niederalkylgruppe.

3. Verbindung zur Verwendung nach Anspruch 1 oder 2, wobei die Verbindung durch die folgenden Strukturen dargestellt wird:


EP 2 616 444 B1



- 5
- 10
- 15
- 20
- 25
- 30
4. Verbindung zur Verwendung nach Anspruch 1 oder 2 oder 3, wobei die eine Wirkung auf mutiertem CFTR-Protein hat, wobei das CFTR-Mutation eine Mutation  $\Delta F508$ -CFTR oder eine andere Mutation der Klasse II ist, und wobei die Mutation  $\Delta F508$ -CFTR oder eine andere Mutation der Klasse II in einer CFTR-Proteinfehlfunktion beteiligt sind.
  5. Verbindung zur Verwendung nach Anspruch 4, wobei die mit CFTR-Proteinfehlfunktion verbundene Krankheit zystische Fibrose ist.
  6. Modulator der Formel (I) nach Anspruch 1, zur Verwendung in der Behandlung von zystischer Fibrose, wobei er eine Wirkung auf CFTR-abhängigen Ionentransport durch Zellmembranen hat und/oder er in der Lage ist, die Anzahl der mutierten CFTR-Proteine zu erhöhen, die Zelloberfläche erreichen.
  7. Modulator der Formel (I) nach Anspruch 1, zur Verwendung in der Behandlung von zystischer Fibrose, wobei er eine stabilisierende Wirkung auf die Struktur des mutierten CFTR-Proteins hat und/oder die Interaktion mit zellulären Proteinen blockiert, die für den vorzeitigen Abbau des mutierten CFTR verantwortlich sind.
  8. Modulator der Formel (I) nach Anspruch 1, zur Verwendung in der Behandlung von zystischer Fibrose, wobei er eine Wirkung auf mutierten CFTR-Protein hat, wobei das CFTR-Mutation eine Mutation  $\Delta F508$ -CFTR oder eine andere Mutation der Klasse II ist.

Revendications

- 35
1. Composé décrit par la formule (I) :



45 ses tautomères, isomères géométriques E et Z, formes optiquement actives telles que les énantiomères, les diastéréoisomères, et ses formes racémiques ou les mélanges de ses formes stéréoisomères, ses sels pharmaceutiquement acceptables ou les complexes de ceux-ci,

où Z<sup>1</sup> est choisi indépendamment parmi les groupes comprenant :

50 une chaîne ramifiée ou non ramifiée de formule -C<sub>n</sub>H<sub>(2n)</sub>-, où n est 1 à 5; une chaîne ramifiée ou non ramifiée en conformation E ou Z de formule -C<sub>n</sub>H<sub>(2n-2)</sub>-, où n est 2 à 5; une chaîne ramifiée ou non ramifiée de formule -C<sub>n</sub>H<sub>(2n-4)</sub>-, où n est 2 à 5; -CR<sup>1</sup>H-, -C<sub>2</sub>H<sub>3</sub>R<sup>1</sup>-, E ou Z -C<sub>2</sub>HR<sup>1</sup>-, -C<sub>3</sub>H<sub>5</sub>R<sup>1</sup>-, E ou Z -C<sub>3</sub>H<sub>3</sub>R<sup>1</sup>-, -CH<sub>2</sub>-, -CH<sub>2</sub>O-, -NR<sup>1</sup>CH<sub>2</sub>-, -CH<sub>2</sub>NR<sup>1</sup>-; où R<sup>1</sup> est un élément choisi indépendamment parmi les groupes comprenant: -H, un halogène, -NH<sub>2</sub>, -OH, -CN, CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -SH, -SCN, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>; où R<sup>2</sup> est un élément choisi indépendamment parmi les groupes comprenant: -H, -CH<sub>3</sub>, -C<sub>2</sub>H<sub>5</sub>, où R<sup>1</sup> et R<sup>2</sup> représentent des éléments choisis indépendamment parmi les groupes aromatiques ou les groupes hétéroaromatiques;

55 comme modulateur de la fonction de protéine CFTR mutée, pour une utilisation dans le traitement de la mucoviscidose.


EP 2 616 444 B1

2. Composé pour une utilisation selon la revendication 1, dans lequel R<sup>1</sup> et R<sup>2</sup> sont des éléments choisis indépendamment dans le groupe décrit par la formule (Ia):



- dans lequel A<sub>1</sub>, A<sub>2</sub>, A<sub>3</sub>, A<sub>4</sub>, A<sub>5</sub>, A<sub>6</sub> représentent des éléments choisis indépendamment parmi les atomes N ou C, étant donné que le nombre d'éléments N constituant l'anneau est 0 à 3; où E<sup>1</sup>, E<sup>2</sup>, E<sup>3</sup>, E<sup>4</sup>, E<sup>5</sup> représentent des éléments optionnels choisis parmi: -OR<sub>B</sub>, -OC(=O)R<sub>C</sub>, -OC(=O)OR<sub>B</sub>, -OC(=O)N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -C(=O)R<sub>C</sub>, -C(=O)N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -C(=O)N(OR<sub>B</sub>)R<sub>A</sub>, -C(=O)OR<sub>B</sub>, -C(=S)R<sub>C</sub>, -C(=O)C(=O)R<sub>C</sub>, -CH<sub>2</sub>OR<sub>B</sub>, -CH<sub>2</sub>CH<sub>2</sub>OR<sub>B</sub>, -CH<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -CH<sub>2</sub>CH<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -CH<sub>2</sub>OCH<sub>2</sub>R<sub>C</sub>, -CH<sub>2</sub>N(R<sub>A</sub>)CH<sub>2</sub>R<sub>C</sub>, -SR<sub>D</sub>, -S(=O)R<sub>D</sub>, -SO<sub>2</sub>R<sub>D</sub>, -SO<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -SO<sub>3</sub>R<sub>B</sub>, -N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -N(R<sub>A</sub>)C(=O)OR<sub>B</sub>, -N(R<sub>A</sub>)C(=O)N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -N(R<sub>A</sub>)SO<sub>2</sub>R<sub>D</sub>, -N(R<sub>A</sub>)SO<sub>2</sub>N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -N(R<sub>A</sub>)C(=O)OR<sub>B</sub>, -N(R<sub>A</sub>)N(R<sub>A</sub>)R<sub>A</sub>'<sup>1</sup>, -N(R<sub>A</sub>)N(R<sub>A</sub>)C(=O)R<sub>C</sub>, -NO<sub>2</sub>, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -NH<sub>2</sub>, -SCN, -SO<sub>2</sub>CN, -F, Cl, -Br, -I, -PO<sub>3</sub>H<sub>2</sub>, -OPO<sub>3</sub>H<sub>2</sub>, une chaîne ramifiée ou non ramifiée de formule -C<sub>n</sub>H<sub>2n</sub>R<sub>C</sub>, où n est 1 à 5, une chaîne ramifiée ou non ramifiée en conformation Z ou E de formule -C<sub>n</sub>H<sub>(2n-2)</sub>R<sub>C</sub>, où n est 2 à 5, une chaîne ramifiée ou non ramifiée de formule -C<sub>n</sub>H<sub>(2n-4)</sub>R<sub>C</sub>, où n est 2 à 5; où R<sub>A</sub>, R<sub>A</sub>'<sup>1</sup>, R<sub>A</sub>'<sup>2</sup> représentent des éléments choisis indépendamment parmi les groupes comprenant: -H, un groupe alkyle inférieur, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OH; où R<sub>B</sub> représente un élément choisi indépendamment parmi: -H, un groupe alkyle inférieur, CN, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, -CH<sub>2</sub>Cl, -CH<sub>2</sub>Br, -CH<sub>2</sub>I; où R<sub>C</sub> représente un élément choisi indépendamment parmi: -H, un groupe alkyle inférieur, CN, CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, CH<sub>2</sub>Cl, CH<sub>2</sub>Br, CH<sub>2</sub>I, F, Cl, Br, I, NH<sub>2</sub>; où R<sub>D</sub> représente un élément choisi indépendamment parmi: -H, un groupe alkyle inférieur.

- 30 3. Composé pour une utilisation selon la revendication 1 ou 2, où ledit composé est choisi parmi les composés:



- 45 4. Composé pour une utilisation selon la revendication 1, 2 ou 3, où ledit composé influe sur la protéine CFTR mutée, étant donné que la mutation de la protéine CFTR est la mutation ΔF508-CFTR ou une autre mutation du groupe II et lorsque la mutation ΔF508-CFTR ou une autre mutation du groupe II est liée aux troubles de fonctionnement normal de la protéine CFTR.
- 50 5. Composé pour une utilisation selon la revendication 4, où la maladie liée aux troubles de fonctionnement normal de la protéine CFTR est la mucoviscidose.
- 55 6. Modulateur défini par la formule (I) selon la revendication 1, pour une utilisation dans le traitement de la mucoviscidose, où le composé influe sur le flux d'ions CFTR-dépendant à travers la membrane plasmique et/ou augmente la quantité de protéine CFTR mutée, qui atteint la membrane plasmique.
7. Modulateur défini par la formule (I) selon la revendication 1, pour une utilisation dans le traitement de la mucoviscidose, où le composé influe sur la stabilisation de structure de la protéine CFTR mutée et/ou bloque l'interaction avec les protéines cellulaires responsables de la dégradation prématurée du mutant CFTR.

## EP 2 616 444 B1

8. Modulateur défini par la formule (I) selon la revendication 1, pour une utilisation dans le traitement de la mucoviscidose, où le composé influe sur la protéine CFTR mutée, étant donné que la mutation de la protéine CFTR est la mutation  $\Delta F508$ -CFTR ou une autre mutation du groupe II.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- WO 2007075901 A [0007]
- WO 2005120497 A [0008]
- US 20080319008 A [0008]
- WO 2009051910 A [0009]
- US 5948814 A [0010]
- US 20040006127 A [0011]
- WO 2006101740 A [0012]
- US 20080318984 A [0012]
- WO 2009051909 A [0013]

## Non-patent literature cited in the description

- **OLLERO M ; BROUILLARD F ; EDELMAN A.** Cystic fibrosis enters the proteomics scene: new answers to old questions. *Proteomics*, July 2006, vol. 6 (14), 4084-99 [0054]
- **RIORDAN JR ; ROMMENS JM ; KEREM B ; ALON N ; ROZMAHEL R ; GRZELCZAK Z et al.** Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*, 08 September 1989, vol. 245 (4922), 1066-73 [0054]
- **ROMMENS JM ; IANNUZZI MC ; KEREM B ; DRUMM ML ; MELMER G ; DEAN M et al.** Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science*, 08 September 1989, vol. 245 (4922), 1059-65 [0054]
- **CASTELLANI C ; CUPPENS H ; MACEK M, JR. ; CASSIMAN JJ ; KEREM E ; DURIE P et al.** Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros*, May 2003, vol. 7 (3), 179-96 [0054]
- **WELSH MJ ; SMITH AE.** Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Celi*, 02 July 1993, vol. 73 (7), 1251-4 [0054]
- **WILSCHANSKI M ; ZIELENSKI J ; MARKIEWICZ D ; TSUI LC ; COREY M ; LEVISON H et al.** Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. *J Pediatr*, November 1995, vol. 127 (5), 705-10 [0054]
- **WARD CL ; OMURA S ; KOPITO RR.** Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell*, 06 October 1995, vol. 83 (1), 121-7 [0054]
- **BOBADILLA JL ; MACEK M, JR. ; FINE JP ; FARRELL PM.** Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. *Hum Mutat*, June 2002, vol. 19 (6), 575-606 [0054]
- **LEWIS HA ; ZHAO X ; WANG C ; SAUDER JM ; ROONEY I ; NOLAND BW et al.** Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. *J Biol Chem*, 14 January 2005, vol. 280 (2), 1346-53 [0054]
- **SCHWIEBERT EM ; BENOS DJ ; EGAN ME ; STUTTS MJ ; GUGGINO WB.** CFTR is a conductance regulator as well as a chloride channel. *Physiol Rev*, January 1999, vol. 79 (1), S145-66 [0054]
- **REDDY MM ; LIGHT MJ ; CJUINTON PM.** Activation of the epithelial Na<sup>+</sup> channel (ENaC) requires CFTR Cl<sup>-</sup> channel function. *Nature*, 18 November 1999, vol. 402 (6759), 301-4 [0054]
- **AHMED N ; COREY M ; FORSTNER G ; ZIELENSKI J ; TSUI LC ; ELLIS L et al.** Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. *Gut*, August 2003, vol. 52 (8), 1159-64 [0054]
- **RIORDAN JR.** Assembly of functional CFTR chloride channels. *Annu Rev Physiol*, 2005, vol. 67, 701-18 [0054]
- **ALLEN MP ; TILDESLEY DJ.** Computer simulation of liquids. Clarendon Press, 1987 [0054]
- **JUNGAS, T. et al.** Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator. *J Biol Chem*, 2002, vol. 277 (31), 27912-8 [0054]
- **ANTIGNY, F. et al.** Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. *Cell calcium*, 2008, vol. 43, 175-83 [0054]
- **BAUDOIN-LEGROS, M. et al.** Control of basal CFTR gene expression by bicarbonate-sensitive adenylyl cyclase in human pulmonary cells. *Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology*, 2008, vol. 21, 75-86 [0054]


## EP 2 616 444 B1

- **BENSALEM, N. et al.** Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. *Molecular & cellular proteomics : MCP*, 2005, vol. 4, 1591-601 [0054]
- **LIPECKA, J. et al.** Distribution of CIC-2 chloride channel in rat and human epithelial tissues. *American journal of physiology. Cell physiology*, 2002, vol. 282, C805-16 [0054]
- **MARIVINGT-MOUNIR, C et al.** Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. *J Med Chem*, 2004, vol. 47 (4), 962-72 [0054]
- **BECQ, F. et al.** Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. *J Biol Chem*, 1999, vol. 274 (39), 27415-25 [0054]
- **HINZPETER, A. et al.** Association between Hsp90 and the CIC-2 chloride channel upregulates channel function. *American journal of physiology. Cell physiology*, 2006, vol. 290, C45-56 [0054]
- **TANGUY, G et al.** CSN5 binds to misfolded CFTR and promotes its degradation. *Biochimica et biophysica acta*, 2008, vol. 1783, 1189-99 [0054]
- **SERMET-GAUDELUS, I. et al.** Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. *Thorax*, 2010, vol. 65, 539-44 [0054]
- **NOREZ, C. et al.** Maintaining low Ca<sup>2+</sup> level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. *Traffic (Copenhagen, Denmark)*, 2006, vol. 7, 562-73 [0054]
- **NOREZ, C. et al.** Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. *FEBS letters*, 2006, vol. 580, 2081-6 [0054]

Mutáns CFTR protein modulátor vegyületek és azok alkalmazása CFTR protein működési rendellenességgel összefüggő betegségek kezelésére

Szabadalmi igénypontok

1. (I):



általános képletű vegyület, annak tautomerjei, E és Z geometriai izomerjei, optikailag aktív formái, így enantiomerjei, diasztereomerjei és racemát formái, vagy a sztereoiszomer formák keverékei, vagy gyógyászatilag elfogadható sóik vagy komplexek; ahol  $Z^1$  egymástól függetlenül az alábbi csoportok közül választott:

- $C_nH_{(2n)}$ -, mely elágazó vagy nem-elágazó, ahol n értéke 1 - 5; E vagy Z geometriai konfigurációjú - $C_nH_{(2n-2)}$ - csoport, mely elágazó vagy nem-elágazó, ahol n értéke 2 - 5; - $C_nH_{(2n-4)}$ - csoport, mely elágazó vagy nem-elágazó, ahol n értéke 2 - 5; - $CR'H$ -, - $C_2H_3R'$ -, E vagy Z - $C_2HR'$ -, - $C_3H_5R'$ -, E vagy Z - $C_3H_3R'$ -, - $OCH_2$ -, - $CH_2O$ -, - $NR''CH_2$ -, - $CH_2R''$ -; ahol  $R'$  egymástól függetlenül -H, halogénatom, - $NH_2$ , -OH, -CN,  $CF_3$ , - $CHF_2$ , - $CH_2F$ , -SH, -SCN, - $CH_3$ , és - $C_2H_5$  csoportok közül választott; ahol  $R''$  egymástól függetlenül -H, - $CH_3$ , és - $C_2H_5$  csoportok közül választott; ahol  $R^1$  és  $R^2$  egymástól függetlenül aromás gyűrű vagy heteroaromás gyűrű közül választott, egy mutáns CFTR protein modulátorként cysticus fibrosis kezelésében történő alkalmazásra.

2. Vegyület az 1. igénypont szerinti alkalmazásra, ahol  $R^1$  és  $R^2$  egymástól függetlenül az alábbi (Ia):



képletű csoportból választott,

ahol  $A_1, A_2, A_3, A_4, A_5, A_6$  egymástól függetlenül N vagy C atomok közül választott, ahol a gyűrű 0-3 nitrogénatomot tartalmaz;

ahol  $E^1, E^2, E^3, E^4, E^5$  adott esetben jelenlévő,  $-OR_B, -C(=O)R_C, -OC(=O)OR_B, -OC(=O)N(R_A)R_{A'}, -C(=O)R_C, -C(=O)N(R_A)R_{A'}, -C(=O)N(OR_B)R_A, -C(=O)OR_B, -C(=S)R_C, -C(=O)C(=O)R_C, -CH_2OR_B, -CH_2CH_2OR_B, -CH_{2n}(R_A)R_{A'}, -CH_2CH_{2n}(R_A)R_{A'}, -CH_2OCH_2R_C, -CH_{2n}(R_A)CH_2R_C, -SR_D, -S(=O)R_D, -SO_2R_D, -SO_{2n}(R_A)R_{A'}, -SO_3R_B, -N(R_A)C(=O)R_C, -N(R_A)C(=O)OR_B, -N(R_A)C(=O)N(R_A')R_{A''}, -N(R_A)SO_2R_D, -N(R_A)SO_{2n}(R_A')R_{A''}, -N(R_A)R_{A'}, -N(R_A)C(=O)R_C, -N(R_A)C(=O)OR_B, -N(R_A)N(R_A')R_{A''}, -N(R_A')N(R_A)C(=O)R_C, -NO_2, -CN, -CF_3, -CHF_2, -CH_2F,  $NH_2$ , -SCN, -SO_2CN, -F, Cl, -Br, -I,  $-PO_3H_2, -OPO_3H_2, -CnH_{2n}R_C$ , mely elágazó vagy nem-elágazó, ahol n értéke 1 - 5; E vagy Z geometriai konformációjú  $-C_nH_{(2n-2)}R_C$  csoport, mely elágazó vagy nem-elágazó, ahol n értéke 2 - 5;  $-C_nH_{(2n-4)}R_C$  csoport, mely elágazó vagy nem-elágazó, ahol n értéke 2 - 5, csoportok közül választott;$


ahol  $R_A, R_{A'}, R_{A''}$  mindegyike egymástól függetlenül -H, rövidszénláncú alkilcsoport, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -OH közül választott;

ahol  $R_B$  egymástól függetlenül -H, rövidszénláncú alkilcsoport, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -CH<sub>2</sub>Cl, -CH<sub>2</sub>Br, -CH<sub>2</sub>I csoport közül választott;

ahol  $R_C$  egymástól függetlenül -H, rövidszénláncú alkilcsoport, -CN, -CF<sub>3</sub>, -CHF<sub>2</sub>, -CH<sub>2</sub>F, -CH<sub>2</sub>Cl, -CH<sub>2</sub>Br, -CH<sub>2</sub>I, -F, -Cl, -Br, -I, -NH<sub>2</sub> közül választott;

ahol  $R_D$  egymástól függetlenül -H, rövidszénláncú alkilcsoport közül választott.

3. Vegyület az 1. vagy 2. igénypont szerinti alkalmazásra, mely vegyület az alábbi szerkezetű:



4. Vegyület az 1. vagy 2. vagy 3. igénypont szerinti alkalmazásra, mely a CFTR mutáns proteinre van hatással, ahol a CFTR mutáció egy, és ahol a  $\Delta F508$ -CFTR mutáció, vagy egy másik II osztályú mutáció CFTR protein hibás működésben játszik szerepet.

5. Vegyület a 4. igénypont szerinti alkalmazásra, ahol a CFTR protein hibás működéssel összefüggő betegség cysticus fibrosis.

6. Az 1. igénypont szerinti (I) képletű modulátor, cysticus fibrosis kezelésében történő alkalmazásra, melynek a CFTR-függő sejtmembránon keresztüli iontranszportra van hatása, és/vagy képes a sejtfelületet elérő mutáns CFTR proteinek számának növelésére.

7. Az 1. igénypont szerinti (I) képletű modulátor, cysticus fibrosis kezelésében történő alkalmazásra, melynek stabilizáló hatása van a mutáns CFTR protein szerkezetére és/vagy gátolja a mutáns CFTR idő előtti degradációjáért felelős celluláris proteinekkel történő kölcsönhatást.

8. Az 1. igénypont szerinti (I) képletű modulátor, cysticus fibrosis kezelésében történő alkalmazásra, melynek stabilizáló hatása van a mutáns CFTR proteinre, ahol a CFTR mutáció  $\Delta F508$ -CFTR mutáció, vagy egy másik II osztályú mutáció.

Szentpéteri Zoltán  
Közvetítő  
Szentpéteri Zoltán Ügyviteli Iroda  
H-1067 Budapest, Árkovány út 113.  
Telefon: 461-1000 Fax: 461-1009  
Email: szentpeteri.zoltan@szbz.hu